Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (14)

2023

  1. Unraveling the genetics of transformed splenic marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709

2022

  1. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

    British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155

  2. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 589-598

2020

  1. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

  2. Vitamin D modifies the incidence of graft-versus-host disease after allogeneic stem cell transplantation depending on the Vitamin D Receptor (VDR) polymorphisms

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4616-4623

2018

  1. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

    Leukemia, Vol. 32, Núm. 3, pp. 675-684

  2. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series

    Annals of Hematology, Vol. 97, Núm. 12, pp. 2417-2424

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

2013

  1. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234